These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26705179)

  • 1. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
    Liang X; Wang J; Bai W; Sun R
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
    Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
    Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
    Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
    Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
    Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
    Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
    Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
    Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
    Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
    Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.
    Morichika K; Karube K; Sakihama S; Watanabe R; Kawaki M; Nishi Y; Nakachi S; Okamoto S; Takahara T; Satou A; Shimada S; Shimada K; Tsuzuki T; Fukushima T; Morishima S; Masuzaki H
    Am J Surg Pathol; 2021 Jun; 45(6):832-840. PubMed ID: 33899787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases.
    Sugitani A; Fukuhara S; Shibata M; Ichihara R; Furukawa H; Maeshima AM
    J Clin Exp Hematop; 2023 Sep; 63(3):181-186. PubMed ID: 37518270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.
    Ahmed AM; Abdel-Hakeem SS; Amine MAF; Yassin EH; Badary FAM
    Int J Exp Pathol; 2023 Jun; 104(3):128-139. PubMed ID: 36974470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Bcl-2 Expression in Non-germinal Center B-cell-Like Diffuse Large B-cell Lymphoma.
    Alford D; Petković I
    Cureus; 2024 Jun; 16(6):e62031. PubMed ID: 38989351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
    Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
    Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm.
    Ananthamurthy A; Murali M
    Indian J Pathol Microbiol; 2023 Nov; ():. PubMed ID: 38394429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.
    Radotra BD; Parkhi M; Chatterjee D; Yadav BS; Ballari NR; Prakash G; Gupta SK
    Surg Neurol Int; 2020; 11():424. PubMed ID: 33365186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nodal T-follicular helper cell lymphoma, angioimmunoblastic-type associated with diffuse large B-cell lymphoma: a clinicopathological study].
    Wang GN; Zhao WG; Zhang DD; Zhang YP; Liu EJ; Lu SS; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):918-923. PubMed ID: 37670621
    [No Abstract]   [Full Text] [Related]  

  • 18. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
    Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
    Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung intravascular large B-cell lymphoma with ground glass opacities on chest computed tomography: a case report.
    Xiao D; Fu C; Long X; Liu W; Chen C; Zhou J; Fan S
    Int J Clin Exp Pathol; 2014; 7(8):5285-90. PubMed ID: 25197411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.